All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
Christian ThiedeThe virtual AML Hub Satellite Symposium at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) brought together an international panel of experts to discuss how measurable residual disease (MRD) impacts outcome of stem cell transplantation in AML, now and in the future. Professor Christian Thiede, Technical University of Dresden, Dresden, DE, presented the topic ‘New developments in molecular MRD assessment in AML.’
Professor Christian Thiede outlines the recently published European LeukemiaNet (ELN) Working Party recommendations for molecular assessment of MRD in AML. Then, he highlights the benefits of using next-generation sequencing (NGS) for MRD detection. Very recent developments, such as NGS of sorted cells and single cell sequencing, could represent highly sensitive and data-rich options for future molecular MRD assessment in AML.
New developments in molecular MRD assessment in AML
Your opinion matters
When treating a patient newly diagnosed with IDH1-mutated AML who is ineligible for intensive chemotherapy, which initial treatment approach would you most likely consider?